Metabolism of adrenal androgen and its impacts on prostate cancer after castration

Chinese Medical Journal

Volumn 121, Issue 4, 2008, Pages 369-374

  Hu, Ming Qiu ^a   Na, Yan Qun ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Adrenal; Androgen; Prostate cancer

Indexed keywords

AMINOGLUTETHIMIDE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANDROSTENEDIONE; ANTIANDROGEN; FLUTAMIDE; GONADORELIN; GONADORELIN AGONIST; HYDROCORTISONE; KETOCONAZOLE; PRASTERONE SULFATE; TESTOSTERONE;

ADRENALECTOMY; ANDROGEN METABOLISM; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CASTRATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENE AMPLIFICATION; HUMAN; HYPOPHYSECTOMY; MONOTHERAPY; NONHUMAN; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; RECEPTOR AFFINITY; SURVIVAL RATE; ADRENAL GLAND; MALE; METABOLISM; ORCHIECTOMY; PATHOLOGY; PROSTATE TUMOR; REVIEW;

ADRENAL GLANDS; ANDROGENS; GENE AMPLIFICATION; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 41649097381     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200802020-00016     Document Type: Article

References (37)

1. Ye DW. Epidemiology of prostate cancer and the trend of its prevalence in China. Chin J Surg (Chin) 2006; 44: 362-364.
2. Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS. Secondary hormonal therapy for advanced prostate cancer. J Urol 2006; 175: 27-34.
3. Partin AW, Rodriguez R. The molecular biology, endocrinology and physiology of the prostate and seminal vesicles. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, Kavoussi LR, Novick AC, et al, eds. Campell's urology, 8th ed. Philadelphia: Elsevier Science; 2002: 1237-1296.
4. Hsing AW, Reichardt JKV, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate 2002; 52: 213-235.
5. Aizawa K, Iemitsu M, Maeda S, Jesmin S, Otsuki T, Mowa CN, et al. Expression of steroidogenic enzymes and synthesis of sex steroid hormones from DHEA in skeletal muscle of rats. Am J Physiol Endocrinol Metab 2007; 292: E577-E584.
6. Siiteri PK. The continuing saga of dehydroepiandrostenedione (DHEA). J Clin Endocrinol Metab 2005; 90: 3795-3796.
7. Labrie F, Luu-The V, Belanger A, Lin SX, Simard J, Pelletier G, et al. Is dehydroepiandrosterone a hormone? J Endocrinol 2005; 187: 169-196.
8. Mueller A, Cupisti S, Binder H, Hoffmann I, Kiesewetter F, Beckmann MW, et al. Endocrinological markers for assessment of hyperandrogenemia in hirsute women. Horm Res 2007; 67: 35-41.
9. Geller J. Basis for hormonal management of advanced prostate cancer. Cancer 1993; 71 (Suppl): 1039-1045.
10. Kashiwagi B, Shibata Y, Ono Y, Suzuki R, Honma S, Suzuki K. Changes in testosterone and dihydrotestosterone levels in male rat accessory sex organs, serum, and seminal fluid after castration: establishment of a new highly sensitive simultaneous, androgen measurement method. J Androl 2005; 26: 586-591.
11. Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK, et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 2006; 91: 3850-3856.
12. Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 2004; 10: 7121-7126.
13. Mohler JL, Gregory CW, Ford OH 3rd, Kim D, Weaver CM, Petrusz P, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10: 440-448.
14. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005; 11: 4653-4657.
15. Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, et al. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 2004; 64: 765-771.
16. So A, Gleave M, Hurtado-Col A, Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J Urol 2005; 23: 1-9.
17. Brown RS, Edwards J, Dogan A, Payne H, Harland SJ, Bartlett JM, et al. Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J Pathol 2002; 198: 237-244.
18. Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate -cancer. Br J Cancer 2003; 89: 552-556.
19. Latil A, Bieche I, Vidaud D, Lidereau R, Berthon P, Cussenot O, et al. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 2001; 61: 1919-1926.
20. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001; 61: 3550-3555.
21. Palmberg C, Koivisto P, Kakkola L, Tarnmela TL, Kallioniemi OP, Visakorpi T. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 2000; 164: 1992-1995.
22. Ricciardelli C, Choong CS, Buchanaan G, Vivekanandan S, Neufing P, Stahl J, et al. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organed confined disease. Prostate 2005; 63: 19-28.
23. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate.cancer. Cancer Res 2006; 66: 2815-2825.
24. Haapala K, Kuukasjarvi T, Hyytinen E, Rantala I, Helin HJ, Koivisto PA. Androgen receptor amplification is associated with increased cell proliferation in prostate cancer. Hum Pathol 2007; 38: 474-418.
25. Gregory CW, Johnson RT, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001; 61: 2892-2898.
26. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001; 61: 4315-4319.
27. Koh E, Kanaya J, Namiki M. Adrenal steroids in human prostatic cancer cell lines. Arch Androl 2001; 46: 117-125.
28. Nakamura Y, Suzuki T, Nakabayashi M, Endoh M, Sakamoto K, Mikami Y, et al. In situ androgen producing, enzymes in human prostate cancer. Endoc Relat Cancer 2005; 12: 101-107.
29. Scholz M, Jennrich R, Strum S, Brosman S, Johnson H, Lam R. Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone. J Urol 2005; 173: 1947-1952.
30. Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate Cancer patients: a phase III.trial (CALGB 9583). J Clin Oncol 2004; 22: 1025-1033.
31. Kruit WH, Stoter G, Klijn JG. Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy. Anticancer Drugs 2004; 15: 843-847.
32. Ueno S, Namiki M, Fukagai T, Ehara H, Usami M, Akaza H. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study. Int J Urol 2006; 13: 1494-1500.
33. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al. American Society of Clinical Oncology. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25: 1596-1605.
34. Collette L, Studer UE, Schroder FH, Denis LJ, Sylvester RJ. Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences. Prostate 2001; 48: 29-39.
35. Schmitt B, Bennett C, Seidenfeld J, Samson D, Wilt T. Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev 2000; (2): CD001526.
36. Oka H, Negoro H, Sugino Y, Iwamura H, Moroi S, Kawakita M. Change of serum adrenal androgens in prostatic cancer patients after bilateral orchiectomy or LHRH agonist treatment. Hinyokika Kiyo 2003; 49: 521-525.
37. Ohlson N, Wikstrom P, Stattin P, Bergh A. Cell proliferation and apoptosis in prostate tumours and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment. Prostate 2005; 62: 307-315.